JP2019519529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519529A5 JP2019519529A5 JP2018561669A JP2018561669A JP2019519529A5 JP 2019519529 A5 JP2019519529 A5 JP 2019519529A5 JP 2018561669 A JP2018561669 A JP 2018561669A JP 2018561669 A JP2018561669 A JP 2018561669A JP 2019519529 A5 JP2019519529 A5 JP 2019519529A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- seq
- nos
- domain comprises
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 238000003259 recombinant expression Methods 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000005754 cellular signaling Effects 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022089863A JP2022130396A (ja) | 2016-05-27 | 2022-06-01 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
| JP2024112931A JP2024156707A (ja) | 2016-05-27 | 2024-07-12 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342394P | 2016-05-27 | 2016-05-27 | |
| US62/342,394 | 2016-05-27 | ||
| PCT/US2017/034691 WO2017205747A1 (en) | 2016-05-27 | 2017-05-26 | Flt3-specific chimeric antigen receptors and methods using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089863A Division JP2022130396A (ja) | 2016-05-27 | 2022-06-01 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019519529A JP2019519529A (ja) | 2019-07-11 |
| JP2019519529A5 true JP2019519529A5 (enExample) | 2020-07-09 |
Family
ID=59054226
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561669A Pending JP2019519529A (ja) | 2016-05-27 | 2017-05-26 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
| JP2022089863A Pending JP2022130396A (ja) | 2016-05-27 | 2022-06-01 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
| JP2024112931A Pending JP2024156707A (ja) | 2016-05-27 | 2024-07-12 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089863A Pending JP2022130396A (ja) | 2016-05-27 | 2022-06-01 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
| JP2024112931A Pending JP2024156707A (ja) | 2016-05-27 | 2024-07-12 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11299546B2 (enExample) |
| EP (2) | EP4413999A3 (enExample) |
| JP (3) | JP2019519529A (enExample) |
| AU (1) | AU2017271606B2 (enExample) |
| CA (1) | CA3025516A1 (enExample) |
| WO (1) | WO2017205747A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017271606B2 (en) * | 2016-05-27 | 2024-08-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | FLT3-specific chimeric antigen receptors and methods using same |
| FI3688032T3 (fi) | 2017-09-26 | 2025-12-09 | Cero Therapeutics Holdings Inc | Kimeerisiä nielaisureseptorimolekyylejä ja käyttömenetelmiä |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| AU2019243154A1 (en) | 2018-03-28 | 2020-10-01 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| EP3902836A4 (en) | 2018-12-18 | 2022-08-31 | Boehringer Ingelheim IO Canada Inc. | FLT3 AGONISTIC ANTIBODIES AND THEIR USES |
| US20220160771A1 (en) * | 2019-04-10 | 2022-05-26 | Iulia Diaconu | Flt3-specific chimeric antigen receptors and methods of using the same |
| SG11202111130SA (en) * | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
| US20210253696A1 (en) * | 2020-01-21 | 2021-08-19 | Cero Therapeutics, Inc. | Bivalent chimeric engulfment receptors and uses thereof |
| WO2021222793A1 (en) * | 2020-04-30 | 2021-11-04 | The Regents Of The University Of Colorado, A Body Corporate | Multispecific anti-flt3 chimeric antigen receptors |
| CN116410315A (zh) * | 2021-12-31 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| JP2004511425A (ja) | 2000-02-08 | 2004-04-15 | ザ ペン ステート リサーチ ファウンデーション | 免疫療法に使用されるインターロイキン１３受容体サブユニットアルファー２ |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US20160015750A1 (en) * | 2013-03-09 | 2016-01-21 | Baylor College Of Medicine | Vascular-targeted t-cell therapy |
| JP6943568B2 (ja) | 2013-12-06 | 2021-10-06 | アメリカ合衆国 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| BR112017001242A2 (pt) * | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| WO2016075612A1 (en) * | 2014-11-12 | 2016-05-19 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| JP7054924B2 (ja) | 2015-09-23 | 2022-04-15 | サイトイミューン セラピューティクス， インコーポレイテッド | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
| AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| EP3436037A4 (en) * | 2016-03-31 | 2019-12-04 | University of Southern California | HIGHLY SENSITIVE AND SPECIFIC LUCIFERASE-BASED REPORTER TEST FOR ANTIGEN DETECTION |
| AU2017271606B2 (en) * | 2016-05-27 | 2024-08-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | FLT3-specific chimeric antigen receptors and methods using same |
| WO2021222793A1 (en) * | 2020-04-30 | 2021-11-04 | The Regents Of The University Of Colorado, A Body Corporate | Multispecific anti-flt3 chimeric antigen receptors |
-
2017
- 2017-05-26 AU AU2017271606A patent/AU2017271606B2/en active Active
- 2017-05-26 US US16/304,552 patent/US11299546B2/en active Active
- 2017-05-26 EP EP24167685.7A patent/EP4413999A3/en active Pending
- 2017-05-26 EP EP17729627.4A patent/EP3464366A1/en active Pending
- 2017-05-26 JP JP2018561669A patent/JP2019519529A/ja active Pending
- 2017-05-26 CA CA3025516A patent/CA3025516A1/en active Pending
- 2017-05-26 WO PCT/US2017/034691 patent/WO2017205747A1/en not_active Ceased
-
2022
- 2022-03-08 US US17/689,698 patent/US12202902B2/en active Active
- 2022-06-01 JP JP2022089863A patent/JP2022130396A/ja active Pending
-
2024
- 2024-07-12 JP JP2024112931A patent/JP2024156707A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519529A5 (enExample) | ||
| JP2018531014A5 (enExample) | ||
| EP4282878A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2016502512A5 (enExample) | ||
| JP2018029594A5 (enExample) | ||
| JP2020519298A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| JP2016538830A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| JP2020517635A5 (enExample) | ||
| JP2014534207A5 (enExample) | ||
| JP2018505139A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2018504145A5 (enExample) | ||
| JP2017526361A5 (enExample) | ||
| JP2016532693A5 (enExample) | ||
| JP2019530431A5 (enExample) | ||
| JP2019527557A5 (enExample) | ||
| CN110582488A (zh) | 具有增强功效的免疫效应细胞疗法 | |
| JP2016539096A5 (enExample) | ||
| JP2017528158A5 (enExample) | ||
| JP2018064568A5 (enExample) |